Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 5/20 | 0.52 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.52 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.52 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.52 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.52 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.52 |
| ▸ | TEAD1 | P28347 | 4/20 | 0.41 |
| ▸ | RORC | P51449 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15642803 | 1.00 | PSEN1 (0.52) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2853120 | 1.00 | PSEN1 (0.52) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2860484 | 0.95 | PSEN1 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2860479 | 0.95 | PSEN1 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8268964 | 0.88 | PSEN1 (0.57) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2864221 | 0.88 | PSEN1 (0.57) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2864219 | 0.88 | PSEN1 (0.57) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8268289 | 0.86 | RORC (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL15642855 | 0.84 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2857367 | 0.84 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170258786-A1 | RBP4 ANTAGONISTS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-09-14 | — | — | US | claimed |
| US-20160030422-A1 | RBP4 ANTAGONISTS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-04 | — | — | US | claimed |
| EP-2295406-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-04-23 | — | — | EP | claimed |
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-13 | — | — | US | claimed |
| EP-2295406-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-03-16 | — | — | EP | claimed |
| US-20170258786-A1 | RBP4 ANTAGONISTS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-09-14 | — | — | US | disclosed |
| US-20160030422-A1 | RBP4 ANTAGONISTS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-04 | — | — | US | disclosed |
| US-8853215-B2 | Derivatives of N-acyl-N′-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-10-07 | — | — | US | disclosed |
| EP-2295406-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-04-23 | — | — | EP | disclosed |
| US-8338622-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-25 | — | — | US | disclosed |
| US-8338622-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-25 | — | — | US | disclosed |
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-1805141-B1 | PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (GB) | 2010-01-20 | — | — | EP | disclosed |
| US-7638629-B2 | Piperidines and related compounds for treatment of alzheimer's disease | Merck Sharp & Dohme Ltd, (GB) | 2009-12-29 | — | — | US | disclosed |
| US-7638629-B2 | Piperidines and related compounds for treatment of alzheimer's disease | Merck Sharp & Dohme Ltd, (GB) | 2009-12-29 | — | — | US | disclosed |
| US-7638629-B2 | Piperidines and related compounds for treatment of alzheimer's disease | Merck Sharp & Dohme Ltd, (GB) | 2009-12-29 | — | — | US | disclosed |
| US-20080021043-A1 | Piperidines and Related Compounds for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LTD. (GB) | 2008-01-24 | — | — | US | disclosed |
| US-20080021043-A1 | Piperidines and Related Compounds for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LTD. (GB) | 2008-01-24 | — | — | US | disclosed |
| US-20080021043-A1 | Piperidines and Related Compounds for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LTD. (GB) | 2008-01-24 | — | — | US | disclosed |
| WO-2006043064-A1 | PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LIMITED (GB) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | RBP4, RBP1, FABP4 | PSEN1 1298/4885PSEN2 1290/4885APH1B 1205/4885 |
| US-20160030422-A1 | RBP4 ANTAGONISTS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | RBP4, RBP1, NR2E3 | PSEN1 741/4885PSEN2 519/4885APH1B 1813/4885 |
| US-20080021043-A1 | Piperidines and Related Compounds for Treatment of Alzheimer's Disease | PSEN1, PSEN2, APP | PSEN1 1/4885PSEN2 2/4885APH1B 13/4885 |
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | NES, BMI1, DOT1L | PSEN1 4620/4885PSEN2 4189/4885APH1B 1254/4885 |
| US-20170258786-A1 | RBP4 ANTAGONISTS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | RBP4, RBP1, NR2E3 | PSEN1 741/4885PSEN2 519/4885APH1B 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.